Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With the Sodium-glucose Transport Protein 2 (SGLT2) Inhibitor EmpaGliflozin in patiEnts With Non-alcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

NCT05232071 is registered in ClinicalTrials.gov with Inventiva Pharma as lead sponsor.

NCT NCT05232071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05232071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With the Sodium-glucose Transport Protein 2 (SGLT2) Inhibitor EmpaGliflozin in patiEnts With Non-alcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
Lead sponsor
Inventiva Pharma
Phase
Phase 2
Overall status
Completed
Start date
June 29, 2022
Completion date
June 4, 2024
Enrollment
39 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, nash - nonalcoholic steatohepatitis